考虑近期一线治疗进展后术后残留病灶对上皮性卵巢癌生存的影响:系统综述与荟萃分析
该系统综述与荟萃分析检索2000年1月1日至2022年9月22日发表的随机对照试验和前瞻性临床试验,纳入97项试验、43,260例原发性上皮性卵巢癌患者,采用线性回归模型分析术后残留肿瘤对无进展生存期和总生存期的影响,发现完全细胞减灭率每增加10%,中位总生存期增加12.97%,在接受维持治疗的患者中增幅为19.13%。
要点
- 完全细胞减灭率每增加10%,中位总生存期增加12.97%,不依赖于全身维持治疗的使用。
- 在接受维持治疗的患者亚组中,完全肿瘤清除的效果增强,中位总生存期增加19.13%。
- 初次 presentation 时达到肉眼完全肿瘤清除可显著延长总生存期。
核心结论
- 初次 presentation 的上皮性卵巢癌达到肉眼完全肿瘤清除可显著延长总生存期。
- 即使近期一线治疗取得进展,完全手术细胞减灭的重要性依然成立。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane Library数据库。
- 纳入2000年1月1日至2022年9月22日发表的随机对照试验和前瞻性临床试验。
- 共纳入97项试验、43,260例患者,其中2476例接受聚(ADP-核糖)聚合酶(PARP)抑制剂,6587例接受贝伐珠单抗。
- 构建对数转换中位无进展生存期和总生存期的线性回归模型。
主要发现
- 所有研究的线性回归模型多变量分析显示,完全细胞减灭率每增加10%,中位总生存期增加12.97%,不依赖于全身维持治疗的使用。
- 在接受维持治疗的患者亚组分析中,完全肿瘤清除的效果增强,完全细胞减灭率每增加10%,中位总生存期增加19.13%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current treatment strategies for primary epithelial ovarian cancer (EOC) have significantly evolved, and the value of complete cytoreduction has not yet been reassessed. The study aimed to investigate the impact of residual disease after cytoreductive surgery for EOC on survival outcomes within the recent paradigm of frontline ovarian cancer treatment. METHODS: We searched relevant literature from the MEDLINE, Embase, and Cochrane Library databases to identify randomized controlled trials and prospective clinical trials of primary EOC published between 1 January 2000 and 22 September 2022. To evaluate the impact of postoperative residual tumors on progression-free survival (PFS) and OS, we constructed a linear regression model for log-transformed median PFS and OS. Patients who did or did not receive first-line maintenance therapy were examined. RESULTS: A total of 97 trials with 43,260 patients were included:2476 received poly(ADP-ribose) polymerase (PARP) inhibitors and 6587 received bevacizumab. Multivariable analysis of the linear regression model of all studies revealed that the median OS increased by 12.97% for every 10% increase in complete cytoreduction rates, independent of the use of systemic maintenance. In the subgroup analysis of patients receiving maintenance therapies, the effect of complete tumor clearance was potentiated, with a median OS increase of 19.13% for every 10% increase in complete cytoreduction rates. CONCLUSION: Total macroscopic tumor clearance at the initial presentation of EOC significantly prolongs OS. Our results establish the importance of complete surgical cytoreduction, even after the introduction of recent advances in frontline treatment for EOC.
引用
- Kim JH, Kim SI, Park EY, et al. Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis. Gynecol Oncol. 2023. PMID: 39491079. doi:10.1016/j.ygyno.2023.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。